Heron Therapeutics (HRTX) Stock Price, Quote & News

Company Profile

Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed na...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 251 4400

Website: www.herontx.com

Address:

100 Regency Forest Drive, Suite 300, Cary, United States

keypatience May. 16 at 8:47 AM

$HRTX Bloomberg numbers are inaccurate

1 · Reply

OLYMPICO May. 16 at 8:46 AM

$HRTX any bloomberg figures for May?

0 · Reply

Tacto May. 15 at 10:55 PM

$HRTX Stochastic is at 2, on a scale of 0-100, so there's no question that it is about to bottom out, and we'll be able to resume loading once it bottoms and turns, which will happen next week By the way, the entire sector got beaten to a bloody pulp today, and the Russell was also blasted . .

0 · Reply

ShelbyRG May. 15 at 8:13 PM

$HRTX Way to go CEO . we or down nearly 30% for the week . 65 % or so from 3+ years ago MR. Collard came on board . We are near all time lows . If he's hoping for $0 he's doing a great job !

1 · Reply

JohnnyFootball May. 15 at 8:10 PM

$HRTX wasn’t there a big lawsuit that is still pending? Assuming a win….would that not lift this POS?

0 · Reply

bullishonHRTX May. 15 at 6:40 PM

$HRTX This smells like Esperion to me. Same pattern but let us see how and when this happens. my personal opinion

0 · Reply

ShelbyRG May. 15 at 6:25 PM

$HRTX Well the Market Cap is officially under projected 1 year sales .

0 · Reply

Ckwoods May. 15 at 5:42 PM

$HRTX it would have gone a long way in the earnings call to address the current share price and at least discussing the possiblity of interest they have received with offers for a buyout. Makes me think there hasn’t been any

0 · Reply

Braddog May. 15 at 4:55 PM

$HRTX Mr Collard Please sell this company. You have failed to bring equity to the investors! Nobody wants to buy this A lot of of us are very concerned about losing all of our money that we’ve invested in this company. It’s been over three years

3 · Reply

jacksonjohn750 May. 15 at 4:39 PM

$HRTX is collard posting here? sad!!

0 · Reply

Heron Therapeutics price target lowered to $4 from $6 at H.C. Wainwright

2026-05-11T16:41:43.000Z - 4 days ago

Heron Therapeutics reports Q1 EPS (4c), consensus (2c)

2026-05-11T16:35:58.000Z - 4 days ago

Heron Therapeutics backs FY26 revenue view $173M-$183M, consensus $174.73M

May 11, 2026, 8:30 AM EDT - 4 days ago

Heron Therapeutics Earnings Call Transcript: Q1 2026

May 11, 2026, 8:00 AM EDT - 4 days ago

Heron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms Guidance

Apr 27, 2026, 5:30 PM EDT - 18 days ago

Heron Therapeutics to Report First Quarter 2026 Financial Results on Monday, May 11, 2026

Feb 26, 2026, 8:30 AM EST - 2 months ago

Heron Therapeutics Earnings Call Transcript: Q4 2025

2026-02-26T13:22:25.000Z - 2 months ago

Heron Therapeutics reports Q4 EPS (2c) vs 2c last year

2026-02-26T13:22:12.000Z - 2 months ago

Heron Therapeutics sees FY26 revenue $173M-$183M

Feb 26, 2026, 8:00 AM EST - 2 months ago

Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results

Feb 17, 2026, 8:30 AM EST - 3 months ago

Heron Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026

2026-01-09T14:35:13.000Z - 4 months ago

Heron Therapeutics sees Q4 revenue $40.5M, consensus $39.83M

Jan 9, 2026, 9:29 AM EST - 4 months ago

Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF® Largest Contributor to Q4 Growth

2025-12-04T13:20:23.000Z - 5 months ago

Heron Therapeutics announces APONVIE inclusion in PONV guidelines

Dec 4, 2025, 8:15 AM EST - 5 months ago

Heron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV)

2025-11-04T20:50:12.000Z - 6 months ago

Heron Therapeutics price target lowered to $5 from $6 at Jefferies

Nov 4, 2025, 8:30 AM EST - 6 months ago

Heron Therapeutics Earnings Call Transcript: Q3 2025

2025-11-04T13:05:21.000Z - 6 months ago

Heron Therapeutics reports Q3 EPS (10c), consensus (1c)

2025-11-04T13:05:15.000Z - 6 months ago

Heron Therapeutics sees FY25 revenue $153M-$163M, consensus $156.48M

Nov 4, 2025, 8:00 AM EST - 6 months ago

Heron Therapeutics Announces Q3 2025 Financial Results and Highlights Commercial Progress

Oct 29, 2025, 5:58 PM EDT - 7 months ago

Heron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors

Oct 21, 2025, 4:20 PM EDT - 7 months ago

Heron Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

2025-09-09T21:15:15.000Z - 8 months ago

Heron Therapeutics files $125M mixed securities shelf

2025-09-09T21:10:11.000Z - 8 months ago

Heron Therapeutics files to sell 37.91M shares of common stock for holders

2025-08-15T11:50:16.000Z - 9 months ago

Heron Therapeutics adopts tax benefits preservation plan

Aug 15, 2025, 7:45 AM EDT - 9 months ago

Heron Therapeutics, Inc. Adopts Tax Benefits Preservation Plan to Protect NOL Assets and Shareholder Value

Aug 8, 2025, 8:30 AM EDT - 10 months ago

Heron Therapeutics Earnings Call Transcript: Q2 2025

2025-08-08T11:52:19.000Z - 10 months ago

Heron Therapeutics reports Q2 EPS (2c), consensus (1c)

2025-08-08T11:51:47.000Z - 10 months ago

Heron Therapeutics backs FY25 revenue view $153M-$163M, consensus $158.54M

2025-08-08T11:50:26.000Z - 10 months ago

Heron Therapeutics announces capital restructuring

HTGC

Aug 8, 2025, 7:45 AM EDT - 10 months ago

Heron Therapeutics Announces Q2 2025 Financial Results and Highlights Commercial Progress

Aug 8, 2025, 7:45 AM EDT - 10 months ago

Heron Therapeutics Announces Comprehensive Capital Restructuring to Support Growth and Extend Maturity Profile

HTGC

Aug 8, 2025, 6:00 AM EDT - 10 months ago

Heron Therapeutics Reschedules Second Quarter 2025 Earnings Release and Conference Call to Friday, August 8, 2025

Jul 28, 2025, 9:42 PM EDT - 10 months ago

Heron Therapeutics to Report Second Quarter 2025 Financial Results on Monday, August 11, 2025

2025-06-09T10:10:23.000Z - 1 year ago

Heron Therapeutics initiated with a Buy at H.C. Wainwright

May 6, 2025, 8:00 AM EDT - 1 year ago

Heron Therapeutics Earnings Call Transcript: Q1 2025

May 6, 2025, 7:45 AM EDT - 1 year ago

Heron Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Corporate Updates

May 6, 2025, 7:30 AM EDT - 1 year ago

Heron Therapeutics Announces Settlement with Mylan Related to CINVANTI® and APONVIE® Patent Litigations

Apr 28, 2025, 6:55 PM EDT - 1 year ago

Heron Therapeutics Announces Appointment of Mark Hensley as Chief Operating Officer

Apr 22, 2025, 4:05 PM EDT - 1 year ago

Heron Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, May 6, 2025

Feb 27, 2025, 8:00 AM EST - 1 year ago

Heron Therapeutics Earnings Call Transcript: Q4 2024

Feb 27, 2025, 7:45 AM EST - 1 year ago

Heron Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Updates

Feb 13, 2025, 4:20 PM EST - 1 year ago

Heron Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results On Thursday, February 27, 2025

Dec 23, 2024, 4:05 PM EST - 1 year ago

Heron Therapeutics Announces Corporate Headquarters Relocation to Cary, North Carolina

Dec 3, 2024, 4:36 PM EST - 1 year ago

U.S. District Court Upholds Validity of CINVANTI® Patents

Nov 12, 2024, 8:00 AM EST - 1 year ago

Heron Therapeutics Earnings Call Transcript: Q3 2024

Nov 12, 2024, 7:55 AM EST - 1 year ago

Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance

Nov 4, 2024, 5:00 PM EST - 1 year ago

Heron Therapeutics Announces Appointment of Michael Kaseta to Board of Directors

Oct 29, 2024, 4:05 PM EDT - 1 year ago

Heron Therapeutics to Report Third Quarter 2024 Financial Results On Tuesday, November 12, 2024

Oct 10, 2024, 4:08 PM EDT - 1 year ago

Heron Therapeutics Reaffirms Availability and Ample Supply of CINVANTI®, SUSTOL®, and APONVIE® as Alternatives During the Potential Shortage of Intravenous Fluids

Sep 25, 2024, 8:00 AM EDT - 1 year ago

Heron Therapeutics Announces FDA Approval of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")

Sep 3, 2024, 8:00 AM EDT - 1 year ago

Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer

Aug 6, 2024, 4:30 PM EDT - 1 year ago

Heron Therapeutics Earnings Call Transcript: Q2 2024

Aug 6, 2024, 4:05 PM EDT - 1 year ago

Heron Therapeutics Announces Second Quarter 2024 Financial Results and Narrows Financial Guidance

Jul 30, 2024, 4:05 PM EDT - 1 year ago

Heron Therapeutics to Report Second Quarter 2024 Financial Results On Tuesday, August 6, 2024

Jul 15, 2024, 8:00 AM EDT - 1 year ago

Heron Therapeutics Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System

Jul 2, 2024, 8:00 AM EDT - 2 years ago

Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")

May 29, 2024, 8:05 AM EDT - 2 years ago

Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN")

May 15, 2024, 9:30 AM EDT - 2 years ago

Heron Therapeutics Transcript: Investor Day 2024

May 7, 2024, 8:30 AM EDT - 2 years ago

Heron Therapeutics Earnings Call Transcript: Q1 2024

May 7, 2024, 8:00 AM EDT - 2 years ago

Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates

Apr 24, 2024, 8:00 AM EDT - 2 years ago

Heron Therapeutics to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024

Apr 11, 2024, 4:05 PM EDT - 2 years ago

Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City

Apr 10, 2024, 11:00 AM EDT - 2 years ago

Heron Therapeutics Transcript: 23rd Annual Needham Virtual Healthcare Conference

Mar 28, 2024, 4:05 PM EDT - 2 years ago

Heron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference

Mar 12, 2024, 4:30 PM EDT - 2 years ago

Heron Therapeutics Earnings Call Transcript: Q4 2023

Mar 12, 2024, 4:05 PM EDT - 2 years ago

Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates

Feb 28, 2024, 8:00 AM EST - 2 years ago

Heron Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results On Tuesday, March 12, 2024

Jan 23, 2024, 8:00 PM EST - 2 years ago

Heron Therapeutics Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures

Jan 7, 2024, 5:00 PM EST - 2 years ago

Heron Therapeutics Announces Partnership with CrossLink Life Sciences to Expand Promotional Effort for ZYNRELEF®, the First and Only Non-Opioid Dual Acting Local Anesthetic for Post-Operative Pain

Nov 14, 2023, 4:30 PM EST - 2 years ago

Heron Therapeutics Earnings Call Transcript: Q3 2023

Nov 14, 2023, 4:05 PM EST - 2 years ago

Heron Therapeutics Announces Third Quarter 2023 Financial Results and Updates Financial Guidance

Nov 7, 2023, 4:05 PM EST - 2 years ago

Heron Therapeutics to Report Third Quarter 2023 Financial Results On Tuesday, November 14, 2023

Aug 14, 2023, 4:30 PM EDT - 2 years ago

Heron Therapeutics Earnings Call Transcript: Q2 2023

Aug 14, 2023, 4:05 PM EDT - 2 years ago

Heron Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Updates

Aug 7, 2023, 4:05 PM EDT - 3 years ago

Heron Therapeutics to Report Second Quarter 2023 Financial Results on Monday, August 14, 2023

Jul 24, 2023, 9:02 AM EDT - 3 years ago

Heron Therapeutics Announces Cost Reduction Plan and Restructuring

Jul 24, 2023, 9:00 AM EDT - 3 years ago

Heron Therapeutics Announces $30 Million Private Placement Financing

HTGC

Jun 23, 2023, 4:05 PM EDT - 3 years ago

Heron Therapeutics Announces Appointment of Ira Duarte as Chief Financial Officer

Jun 12, 2023, 9:00 AM EDT - 3 years ago

Heron Therapeutics Announces Appointment of William Forbes, Pharm.D. as Chief Development Officer

May 11, 2023, 4:30 PM EDT - 3 years ago

Heron Therapeutics Earnings Call Transcript: Q1 2023

May 11, 2023, 4:01 PM EDT - 3 years ago

Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2023 and Highlights Recent Corporate Updates

keypatience May. 16 at 8:47 AM

$HRTX Bloomberg numbers are inaccurate

1 · Reply

OLYMPICO May. 16 at 8:46 AM

$HRTX any bloomberg figures for May?

0 · Reply

Tacto May. 15 at 10:55 PM

0 · Reply

ShelbyRG May. 15 at 8:13 PM

$HRTX Way to go CEO . we or down nearly 30% for the week . 65 % or so from 3+ years ago MR. Collard came on board . We are near all time lows . If he's hoping for $0 he's doing a great job !

1 · Reply

JohnnyFootball May. 15 at 8:10 PM

$HRTX wasn’t there a big lawsuit that is still pending? Assuming a win….would that not lift this POS?

0 · Reply

bullishonHRTX May. 15 at 6:40 PM

$HRTX This smells like Esperion to me. Same pattern but let us see how and when this happens. my personal opinion

0 · Reply

ShelbyRG May. 15 at 6:25 PM

$HRTX Well the Market Cap is officially under projected 1 year sales .

0 · Reply

Ckwoods May. 15 at 5:42 PM

0 · Reply

Braddog May. 15 at 4:55 PM

3 · Reply

jacksonjohn750 May. 15 at 4:39 PM

$HRTX is collard posting here? sad!!

0 · Reply

slayer2408 May. 15 at 4:10 PM

$HRTX 14 cents from $1 😱

0 · Reply

chance111 May. 15 at 4:05 PM

$HRTX Just pray for a buyout soon even if it is for $1.25 a share. This will continue to drop for the next 3 months and it will get really ugly. No chance without a buyout. I learned a long time ago that investing based on a possible buyout is foolish. However, at this point, it is our only hope. The people who are raving about percentage increase in sales are apparently not taking into account where sales were at the starting point. !00% increase of a very low sales number means nothing and we have not even seen a 100% increase in sales. Instead of looking at the way you want things to be, start thinking about how things actually are. I am talking to the rational people on here because there is no hope for the delusional posters and we all know who they are. Pray for a buyout!

0 · Reply

Ckwoods May. 15 at 3:49 PM

$HRTX I’m really concerned we may have to reverse split at this point not to get delisted. For any long you can just see the slow steady downtrend with no catalyst for the next 3 months.

1 · Reply

keypatience May. 15 at 3:39 PM

$HRTX @milans100 They have just updated their Q1 presentation file on their website

0 · Reply

Highfade May. 15 at 2:07 PM

$HRTX 80’s, now we our talking! Bargain Friday!!

0 · Reply

bullishonHRTX May. 15 at 1:35 PM

$HRTX Collard when he was brought on board said he wants to bring value to shareholders. I personally trust that based on his antecedent. He has done it before and i dont think Heron will be any different. This is not a financial advice. Do your own DD. But i am good with this though.

0 · Reply

bullishonHRTX May. 15 at 1:05 AM

$HRTX apparently someone reported and blocked my account for being positive on HRTX...funny right? but thanks to stocktwits I a back because I didnt violate any of their rules. Tomorrow is another day.

1 · Reply

Tacto May. 14 at 11:50 PM

$HRTX Order flow was positive today Inflow: 484.03 Outflow: 387.48 . .

0 · Reply

KY3000 May. 14 at 10:06 PM

$HRTX crazy storms this year, next ER will tell the story

0 · Reply

Tacto May. 14 at 10:04 PM

$HRTX Looks like we'll be able to resume loading next week, looking at the Stochastic getting close to bottoming in the lower part of the picture there The FUD puppets are also a good indicator, and they're really pouring it on now.. . .

0 · Reply

jacksonjohn750 May. 14 at 8:06 PM

$HRTX LOL

0 · Reply

slayer2408 May. 14 at 7:35 PM

$HRTX $1 is 7 cents away…. How will the stock ever go up 7 cents. Most people on this board are clowns, grow a pair of balls and STFU.

0 · Reply

Market Cap	172.70M
Revenue (ttm)	154.90M
Net Income (ttm)	-20.20M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-13.04%
Debt to Equity Ratio	7.53

Volume	1,968,700
Avg Vol	2,192,970
Day's Range	N/A - N/A
Shares Out	189.28M
Stochastic %K	0%
Beta	1.70
Analysts	Sell
Price Target	$4.00